



Letter to the Editor

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in a Child with Myelodysplastic Neoplasm with Complex Karyotype and *ETV6* Variant

Keywords: Childhood myelodysplastic neoplasm; Complex karyotype; *ETV6* variant; Hematopoietic stem cell transplantation; Relapse; Clonal cytogenetic evolution.

Published: May 01, 2024

Received: March 14, 2024

Accepted: April 07, 2024

Citation: Almeida Antônio de Kós E., Lamim Lovatel V., de Cássia Barbosa Tavares R., Moura Ferreira G., Gomes B., Silva Bueno A.P., Sobral da Costa E., de Souza Fernandez T. Outcome of allogeneic hematopoietic stem cell transplantation in a child with myelodysplastic neoplasm with complex karyotype and *ETV6* variant. *Mediterr J Hematol Infect Dis* 2024, 16(1): e2024040, DOI: <http://dx.doi.org/10.4084/MJHID.2024.040>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To the editor.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only potentially curative treatment for myelodysplastic neoplasm (MDS).^{1,2,3} However, post-transplant disease relapse emerges as the major cause of treatment failure in MDS patients.^{3,4} Although a standard approach for MDS patients with post-transplant relapse is not established, some salvage therapies have been reported with variable effectiveness.^{3,4} Here, we report a clonal cytogenetic evolution (CCE) in a child with MDS who relapsed after allo-HSCT, showing a complex karyotype and a variant in the *ETV6* at diagnosis.

A three-year-old boy with severe thrombocytopenia, mild macrocytic anemia, leukopenia, and 12% myeloid peripheral blasts was admitted at Instituto de Pediatria e Puericultura Martagão Gesteira, Universidade Federal do Rio de Janeiro, Brazil, in January 2016. Bone marrow (BM) evaluation evidenced marked erythroid dysplasia, megakaryocytic dysplasia, and 14% of myeloid blasts. Cytogenetic analysis of BM cells by G-banding revealed the complex karyotype: 49, XY, del(3)(q21), del(6)(q21),+der(6)del(6)(q21),+8,+der(12)del(12)(p11)[21] (**Figure 1A**). FISH analysis confirmed the +8 (**Figure 1B**). The patient was diagnosed with MDS with increased blasts (MDS-IB).⁵ Next-generation sequencing (NGS) analysis using the Ion Torrent Personal Genome Machine (PGM) platform (Life Technologies) was performed for the genes: *GATA2*, *RUNX1*, *CEBPA*, *ANKRD26*, *ETV6*, *SAMD9*, *SAMD9L*, *PTPN11*, *NRAS*, *SETBP1*, *DDX41*, *TP53*, *FLT3*, *SRP72* and *JAK3*. An *ETV6* likely pathogenic variant was identified, with the molecular consequence of the loss of the termination codon (stop-loss variant) (**Table 1**). He evolved with worsening cytopenias, transfusion requirements, and progression to MDS/AML. He was treated with thioguanine but he did not show response to

this treatment. More intensive chemotherapy was performed for induction of minimal residual disease (MRD); then, he was referred to Bone Marrow Transplantation Center, Instituto Nacional de Cancer, and underwent allo-HSCT from his nine years old female HLA-matched sibling donor, with minor ABO incompatibility. The myeloablative conditioning regimen consisted of busulfan/cyclophosphamide (BU/CY) and graft-versus-host disease (GVHD) prophylaxis of methotrexate (MTX) and cyclosporine (CSA). The engraftment occurred on D+21. BM evaluation at D+45 post-transplant showed negative MRD by flow cytometry, donor karyotype 46, XX[35], and mixed donor chimerism by PCR short tandem repeats (STR) analysis (96.9% in mononuclear cells and 100% in granulocytic population). However, at D+75, peripheral blood and BM analysis revealed pancytopenia, myeloid dysplasia, and a decline in donor chimerism to 87.5% in the mononuclear population. Attempts to carry out preemptive donor lymphocyte infusions (DLIs) did not materialize because the donor had recurrent respiratory infections at that time. The patient received one cycle of azacitidine (AZA) with improvement of hepatomegaly, bone pain, and hematological counts, but soon after, he evolved with severe thrombocytopenia and respiratory infection. At D16 of AZA, the patient showed 2% of blasts compatible with megakaryoblasts and 12% of dysplastic megakaryocytic lineage by flow cytometry. His clinical condition worsened around D+137, with aggravation of pancytopenia due to a progressive decrease in donor chimerism (47.8% in the mononuclear population). At that point, flow cytometry showed 18% of dysplasia in the megakaryocytic sector. Overt disease relapse occurred at D+180 post-HSCT. The cytogenetic analysis showed the CCE: 50, XY, del(3)(q21),+der(3)del(3)(q21),del(6)(q21),




Figure 1. Conventional and molecular cytogenetics of BM cells in pediatric MDS at diagnosis and post-HSCT. **(A)** G-banding showing the complex karyotype: 49,XY,del(3)(q21),del(6)(q21),+der(6)del(6)(q21),+8,+der(12)del(12)(p11); **(B)** FISH analysis using the c-MYC probe (LSI MYC spectrum orange, 8q24, Vysis) showing trisomy 8 (three red signals); **(C)** G-banding analysis post-HSCT showing a cytogenetic clonal evolution: 50,XY,del(3)(q21),+der(3)del(3)(q21),del(6)(q21),+der(6)del(6)(q21),+8,+der(12)del(12)(p11); **(D)** FISH analysis using the c-MYC probe (LSI MYC spectrum orange, 8q24, Vysis) showing cells with trisomy 8 and normal cells (two red signals).

Table 1. NGS analysis detected the *ETV6* variant in a pediatric MDS patient pre-HSCT.

	<i>ETV6</i>
Locus	chr12:12043980
dbSNP	-
Impact	Likely Pathogenic
Consequence	Stop loss
Genotype	A/G
Allele_coverage	A=320, G=11
Allele_ratio	A=0.9668, G=0.0332
Allele_frequency (%)	3.32
MAF	-
Transcript	NM_001987.5
Protein	p.Ter453Trp
Coding	c.1359A>G
Related disease	Bone marrow diseases

+der(6)del(6)(q21),+8,+der(12)del(12)(p11)[2]/46,XX [19] (**Figure 1C**). The patient had 14.2% of positive cells for +8 by FISH (**Figure 1D**). The immunophenotyping showed 5% of blasts, and STR detected mixed donor chimerism in both lineages (59.9% mononuclear and 77.3% in granulocytic populations). Salvage chemotherapy with fludarabine plus cytarabine and idarubicin was started. Despite attempts to control the disease, it progressed; the patient developed severe persistent pancytopenia (with transfusion dependency) and massive pulmonary aspergillosis that led to his death after 8 months post-HSCT.

The complex karyotype is a cytogenetic biomarker indicative of poor survival after HSCT in MDS patients.⁴ The MDS genetic diversity amongst coexisting subclones may result in a more heterogeneous and complex disease, as some of the subclones may be resistant to specific types of therapy.⁶

In the present report, the patient pre-HSCT had a complex karyotype. Post-HSCT, the patient showed disease relapse and CCE, represented by the acquisition of a der(3)del(3)(q21). The del(3)(q21) involves the loss of important genes such as *GATA2*,⁷ *BCL6*⁸ and *MECOM*.⁹ The del(3q) was also present at the abnormal cytogenetic clone detected at diagnosis with other chromosomal abnormalities involving important genes such as *MYB* in del(6)(q21); *c-MYC* in +8; and *ETV6* in del(12)(p11). It is interesting to note the high genomic instability in this patient, who also acquired the gain of these abnormal chromosomes, resulting in chromosome derivatives. These extra copies can lead to overexpression of important genes mapped to these chromosome regions as *FANCD2*, *RASSF1* in 3p; *DEK*, *CDKN1A* in 6p, and *WNT1*, *HOXC13* in 12q.⁸ *ETV6* is subject to heterozygous mutations in hematologic malignancies, including MDS. *ETV6* is a major intrinsic regulator of megakaryocytes.^{10,11} Besides that, *ETV6* is one of the key regulators of sepsis, a major cause of morbidity and mortality in the intensive care unit.¹² In this case, the complex karyotype and the loss of heterozygosity in *ETV6* (chromosomal deletion and genetic variant) may be associated with disease relapse and unfavorable clinical outcome post-transplant. Ertz-Archambault and colleagues observed cytogenetic evolution in myeloid neoplasms in adult patients who had disease recurrence after HSCT. The authors observed that an unfavorable cytogenetic profile at the initial diagnosis may represent an important pre-diagnosis factor of a predisposition for clonal evolution. The acquisition of more complex cytogenetic alterations

is associated with lower survival.⁶ Our study suggests that the treatment of MDS patients with predictive factors of poor prognosis, such as complex karyotypes and *ETV6* variant, remains a challenge. Prospective studies are necessary to characterize the biology of MDS and identify molecular biomarkers associated with disease relapse in order to develop precision medicine to improve the survival of this group of patients.

Acknowledgements. This study was supported by Fundação Carlos Chagas Filho de Amaro à Pesquisa do Estado do Rio de Janeiro (FAPERJ) (FAPERJ/E-26/201.2018/2022) and the Brazilian Ministry of Health (Instituto Nacional de Câncer/INCA, Brazil).

Author Contributions. EAAK, VLL, and TSF wrote the manuscript. TSF designed the study. EAAK and VLL performed the cytogenetic and FISH analysis. RCBT, APB, and ESC analyzed the clinical data. GMF, VLL, and TSF performed the NGS analysis. BEG performed the flow cytometry analysis. TSF and RCBT reviewed critically the manuscript for important intellectual content. All authors have read and approved the manuscript.

Ethics Approval and Consent To Participate. This study was approved by the Ethics and Research Committee of the National Cancer Institute (reference number # 3401739) in accordance with the Declaration of Helsinki. Informed consent was obtained from the children's parents.

Elaiza Almeida Antônio de Kós^{1,2}, Viviane Lamim Lovatel¹, Rita de Cássia Barbosa Tavares³, Gerson Moura Ferreira⁴, Bernadete Gomes⁵, Ana Paula Silva Bueno⁶, Elaine Sobral da Costa⁶, Teresa de Souza Fernandez^{1,2}.

¹ Cytogenetic Laboratory, Cell and Gene Therapy Program, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.

² Post-Graduate Program in Medical Sciences, Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil.

³ Bone Marrow Transplantation Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.

⁴ Stem Cell Laboratory, Instituto Nacional de Câncer, Rio de Janeiro 20230-130, Brazil.

⁵ Immunology Laboratory, Cell and Gene Therapy Program, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.

⁶ Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.

Competing interests: The authors declare no conflict of Interest.

Correspondence to: Teresa de Souza Fernandez. Instituto Nacional de Câncer (INCA), Centro de Transplante de Medula Óssea, Laboratório de Citogenética, Praça Cruz Vermelha nº 23, 6º andar. Centro, Rio de Janeiro, RJ, Brazil. CEP: 20230-130. Tel +55 21 3207-1701. E-mail: teresafernandez@inca.gov.br ORCID: <https://orcid.org/0000-0003-1299-4666>

References:

1. Locatelli F, Strahm B. How I treat myelodysplastic syndromes of childhood. *Blood*. 2018; 131(13):1406-1414. <https://doi.org/10.1182/blood-2017-09-765214> PMID:29438960
2. Hasle H, Niemeyer CM. Advances in the prognostication and management of advanced MDS in children. *Br J Haematol*. 2011; 154(2):185-95. <https://doi.org/10.1111/j.1365-2141.2011.08724.x> PMID:21554264
3. Du Y, Li C, Zhao Z, Liu Y, Zhang C, Yan J. Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. *BMC Cancer*. 2023;23(1):764. <https://doi.org/10.1186/s12885-023-11259-6> PMID:37592239 PMCid:PMC10433628
4. De Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML:

- recommendations from an international expert panel. *Blood*. 2017; 129:1753-1762.
<https://doi.org/10.1182/blood-2016-06-724500>
PMid:28096091 PMCid:PMC5524528
5. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumors: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia* 2022; 36:1703-1719.
<https://doi.org/10.1038/s41375-022-01613-1>
PMid:35732831 PMCid:PMC9252913
6. Ertz-Archambault N, Kosiorek H, Slack JL, Lonzo ML, Greipp PT, et al. Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival. *Biol Blood Marrow Transplant*. 2017; 23(5):782-789.
<https://doi.org/10.1016/j.bbmt.2017.02.003>
PMid:28189903
7. Greenmyer JR, Thompson WS, Hoppman NL, Khan S, Patnaik MS, Schimmenti LA, Kohorst MA. 3q21 deletion affects GATA2 and is associated with myelodysplastic syndrome. *Br J Haematol*. 2022;196(4):1120-1123.
<https://doi.org/10.1111/bjh.17902>
PMid:34651298
8. Atlas of Genetics and Cytogenetics in Oncology and Haematology in 2013. Huret JL, Ahmad M, Arsaban M, et al. *Nucleic Acids Res*. 2013 Jan;41(Database issue):D920-4. doi: 10.1093/nar/gks1082.
<https://doi.org/10.1093/nar/gks1082>
PMid:23161685 PMCid:PMC3531131
9. Voit RA, Sankaran VG. MECOM Deficiency: from Bone Marrow Failure to Impaired B-Cell Development. *J Clin Immunol*. 2023;43(6):1052-1066.
<https://doi.org/10.1007/s10875-023-01545-0>
PMid:37407873
10. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. *N Engl J Med*. 2011;364(26):2496-506.
<https://doi.org/10.1056/NEJMoa1013343>
PMid:21714648 PMCid:PMC3159042
11. Hock H, Shimamura A. ETV6 in hematopoiesis and leukemia predisposition. *Semin Hematol*. 2017;54(2):98-104.
<https://doi.org/10.1053/j.seminhematol.2017.04.005>
PMid:28637624 PMCid:PMC5584538
12. Zhang Z, Chen L, Xu P, Xing L, Hong Y, Chen P. Gene correlation network analysis to identify regulatory factors in sepsis. *J Transl Med*. 2020;18(1):381.
<https://doi.org/10.1186/s12967-020-02561-z>
PMid:33032623 PMCid:PMC7545567